Cantor Fitzgerald upgraded Madrigal Pharmaceuticals (MDGL) to Overweight from Neutral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street
- Madrigal Pharmaceuticals reports Q3 EPS ($5.08) vs ($4.92) last year
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms
- Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA